Renaissance in Specialty Chemicals & Pharmaceutical Intermediates
The Coming Renaissance in Specialty Chemicals & Pharmaceuticals in the US is predicted to return chemical production back to the US. Dependence on China for these compounds since COVID-19 maybe over. The new US plants will depend on Process Intensification instead of old batch processing which will allow these processes to be installed at a much lower cost.
The study at the Pharmaceutical Roundtable shows the importance of process intensification for the pharmaceutical industry in the development of new drug candidates and in their final plant design.2
Continuous Plants or Flow Chemistry
What the chemical industry has calls continuous; the pharmaceutical industry is now calling it flow chemistry.
The current scenario in the pharmaceutical industry, where the quality of the end product is a fundamental priority, justifies the shift from inefficient conventional batch production to continuous production methods.2, 5
What constitutes the beginning and end of a batch is simple to determine. All raw materials are in precise molar ratios so they start raw material totes or tanks together and run out together signifying the end of a batch.
Reducing energy consumption during the purification stage of pharmaceutical products is one of the main objectives of separation and purification techniques, which aim to produce particles of controlled size and purity by controlling crystal birth and growth rates depending on the addition of antisolvents. In this work in the reference, a coiled flow inverter (CFI) used in a novel crystallization device was investigated.5
These two strategies were investigated as a means of controlling crystal size and distribution using CFI technology. This allows for an inherently safer interpretation of the process, which requires understanding and optimization of such reactors for a particular application, as well as the knowledge required to design and understand them for specific applications.2, 7
Multifunctional reactors, novel heat exchanger and separation strategies, including membrane technology, will be at the center of a scale – in numbers that will serve to highlight the industrialization of the development of these reactors and the application of these technologies in a wide range of applications. 7
The fine chemicals industry relies on existing infrastructure, and the continuous flow of processes forms the basis for the production of a wide range of products where high-quality, high-performance operations, such as pharmaceuticals, are driven by a high degree of efficiency and safety. In general, they are much more complex than raw material chemicals and require numerous and very different reaction steps. These continuous processes form the core of the pharmaceutical industry production process, in which the use of high-quality materials and technologies and the integration of new technologies lead to efficient operation. 6
The implementation of these newly developed concepts enables higher yields, which contribute to further cost and energy savings. This makes the production of pharmaceuticals more efficient and cost-effective – effective for the pharmaceutical industry.1,6
The experimental techniques required for the treatment of scalar transport processes are not limited to chemical-technical purposes and will also be used in general experimental fluid mechanics. Radical new technologies have been developed to gradually improve the performance of chemical processes, with applications in other areas of the chemical industry falling under the umbrella of process intensification (PI). The entire process has led to a shift in development strategies within the industry, with the aim of converting traditional batch processes into continuous flows and exploring new operating windows that allow the use of fluid chemistry.1, 4
More recently, such technologies have been optimized and used in pharmaceutical crystallization, providing an opportunity to improve the design and functioning of pharmaceutical crystallization. The success of these technologies is based on the fact that they have enabled the development of a wide range of high-performance, low-cost solutions for the production of new medicines and medicines.4
Sources:
1: https://gtr.ukri.org/projects?ref=EP%2FK035061%2F1
3: https://www.sympla.com.br/brazilian-seminar-on-process-intensification__635689
4: https://www.pharmafocusasia.com/manufacturing/pharmaceutical-crystallisation
5: https://repositorio.tec.mx/handle/11285/629962
